Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy

PRESS RELEASE: 28 August 2018

Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).

Read more

A uniquely designed ALK/EML4 TriCheck FISH probe for lung cancer diagnosis

ZytoVision’s ZytoLight products allow for reliable, highly sensitive and specific detection of genetic aberrations (e.g. translocations, deletions, amplifications and chromosomal aneuploidies) by using fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears, and metaphase chromosome spreads.

Read more
Top